CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

At its annual meeting, the society discussed progress it has made in pushing ahead the Access to Genetic Counselor Services ...

Investigators who designed a base-editing treatment are planning an "umbrella of umbrellas" trial, while others are developing roadmaps to guide personalized treatments.

The drugmaker is paying MeiraGTx $75 million upfront and $400 million in milestone payments to gain access to a treatment for LCA4 caused by AIPL1 mutations.

The firm is preparing a protocol amendment to standardize patient monitoring and management of an immunosuppressive regimen.

Trodelvy didn't improve progression-free survival versus chemo in the post-endocrine therapy first-line HR-positive, HER2-negative advanced breast cancer setting.